Saracatinib. Dual Src/ABL kinase inhibitor oncolytic

Drugs of the Future

Volumn 34, Issue 2, 2009, Pages 106-114

  Dulsat, C ^a   Mealy, N ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTHRALGIA; ARTICLE; ASTHENIA; BONE CANCER; BREAST CANCER; CANCER INVASION; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPNEA; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IC 50; KIDNEY FAILURE; LEUKOPENIA; LOOSE FECES; LUNG CANCER; METASTASIS; MYALGIA; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RASH; SEPTIC SHOCK; SIDE EFFECT; SKIN CANCER; STOMACH CANCER; THYMUS CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 76649114346     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.02.1340647     Document Type: Article

References (77)

1. Ple, P., Hennequin, L.F.A. (AstraZeneca AB; AstraZeneca plc). Quinazoline derivatives for the treatment of tumours. CA 2407371, EP 1292594, JP 2003535859, US 2004214841, US 2006258642, US 7049438, WO 2001094341.
2. Ford, J.G., McCabe, J.F., O'Kearney-McMullan, A. et al. (AstraZeneca AB; AstraZeneca plc). Process for the preparation of 4-(6-chloro-2, 3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-l-yl) ethoxy]-5- tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof. EP 1871769, JP 2008524183, WO 2006064217.
3. Oldham, K., Moore, N.C. (AstraZeneca AB; AstraZeneca plc). Quinazoline derivatives for the treatment of T cell mediated diseases. EP1450808, US 2005038050, US 7160891, WO 2003045395.
4. Hennequin, L.F., Allen, J., Breed, J. et al. N-(5-Chloro-l,3- benzodioxol-4-yt)-7-[2-(4-methylpiperazin-l-yl)ethoxy]-5-(tetrahydro-2H-pyran-4- yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dualspecific c-Src/Abl kinase Inhibitor. J Med Chem 2006, 49(22): 6465-88.
5. Ries, L.A.G., Melbert, D., Krapcho, M. et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007. http://seer.cancer.gov/csr/1975.2004/
6. Maddams, J., Moller, H., Devane, C. Cancer prevalence in the UK, 2008 Thames Cancer Registry and Macmillan Cancer Support, 2008 http://www.thames- cancer-reg.org.uk/news/ukj3revalence-14072008.pdf
7. World Health Organization. http://www.who.int/mediacentre/fact-sheets/ fs297/en/.
8. Russello, S.V., Shore, S.K. SRC in human carcinogenesis. Front Biosci 2004, 1(9): 139-44.
9. Tsygankov, A.Y., Shore, S.K. Src: Regulation, role in human carcinogenesis and pharmacological inhibitors. Curr Pharm Des 2004, 10(15): 1745-56.
10. Hennequin, L.F., Allen, J., Costello, G.F. et al. The discovery of AZD0530: A novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 2537.
11. Nowak, D., Boehrer, S., Hochmuth, S. et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anti-Cancer Drugs 2007, 18(9): 981-95.
12. Herynk, M.H., Beyer, A.R., Cui, Y., Weiss, H., Anderson, E., Green, T.P., Fuqua, S.A.W. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 2006, 5(12): 3023-31.
13. Herynk, M.H., Beyer, A., Cui, Y., Green, T.P., Fuqua, S.A.W. c-Src inhibition with AZD0530 reduces estrogen mediated growth and invasion in breast cancer cells expressing the K303R ERalpha mutant. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 264.
14. Chen, Y., Tan, C.-K., Slingerland, J. The Src inhibitor AZD0530 cooperates with anastrozole to inhibit human breast cancer growth in vitro and in vivo. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 1470.
15. Lopez-Skinner, L.A., Kelley, L., Gatesman-Ammer, A. et al. The novel Src/Abl kinase inhibitor AZD0530 inhibits proliferation, invasion and invadopodia formation in head and neck squamous cell carcinoma. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 3247.
16. Koppikar, P., Choi, S.-H., Egloff, A.M. et al. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 2008, 14(13): 4284-91.
17. Choi, S.-H., Cai, Q., Nozawa, H., Thomas, S.M., Grandis, J.R. Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst LB-178.
18. Nozawa, H., Howell, G., Suzuki, S. et al. Combined inhibition of PLC-gamma-1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 2008, 14(13): 4336-44.
19. Frederick, B., Helfrich, B., Raben, D. AZD0530, a dual-specific Src/Abl tyrosine kinase inhibitor, inhibits migration and invasion without growth inhibition in head and neck squamous cell carcinomas with a mesenchymal phenotype. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 571.
20. Hickinson, M., Curtis, N., Green, T.P., Growcott, J., Curwen, J., Isherwood, B., Carragher, N. Enhanced in vitro anti-invasive activity in A673 rhabdomyosarcoma cells of the specific endothelin-A receptor (ETA) antagonist ZD4054 when combined with the novel Src inhibitor AZD0S30. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 1487.
21. Carragher, N., Isherwood, B., Hickinson, M., Curtis, N., Green, T, Growcott, J., Curwen, J. Application of 3-dimensional (3D) in vitro invasion assays demonstrate anti-invasive activity of the specific endothelin-A (ETA) receptor-antagonist ZD40S4 when combined with the novel Src/Abl inhibitor AZD0530. NCRI Cancer Conf (Oct 5-8, Birmingham) 2008, Abst B77.
22. Dos Santos, L.A., Diaz, J.P., Ma, X., Thapi, D., Yan, X.J., Rosales, N., Spriggs, D.R. The Src inhibitor AZD0530 demonstrates enhanced antiproliferative and anti-invasive activity in MUC16+ A2780 ovarian carcinoma cells. 39th Annu Meet Women's Cancer (March 9-12, Tampa) 2008, Abst 108.
23. Chang, Y-M., Bai, L., Yang, J.C., Kung, H.-J., Evans, C.P. AZD0530 is a novel SRC kinase inhibitor with anti-proliferation and anti-migration properties in prostate cancer. J Urot [Annu Meet Am Urol Assoc (AUA) (May 19-24, Anaheim) 2007] 2007, 177(4, Suppl.): Abst 532.
24. Yang, J.C, Bai, L., Kung, H.-J., Evans, C.P. Effect of the specific Src kinase inhibitor AZD0530 on osteolytic lesions in prostate cancer. J Urol [Annu Meet Am Urol Assoc (AUA) (May 17-22, Orlando) 2008] 2008, 179(4, Suppl.): Abst 1137.
25. Klein-Nulend, J., Van Duin, M.A., Green, T.P., Everts, V., De Vries, T.J. The dual specific Src/Abl kinase inhibitor AZD0530 inhibits the formation and activity of human osteoclasts. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3602.
26. De Vries, T.J., Van Duin, M., Green, T., Everts, V., Klein-Nulend, J. C-SRC kinase inhibitor AZD0530 inhibits the formation and activity of human osteoclasts. Calcif Tissue Int [34th Eur Symp Calcif Tissues (ECTS) (May 5-9, Copenhagen) 2007] 2007, 80(Suppl. 1): Abst P197-S.
27. Campbell, K.A., Ren, L., Hong, S.-H., Helman, L.J., Khanna, C. Inhibition of the metastatic potential of the osteosarcoma cell lines by the Src/Abl kinase inhibitor AZD0530. Proc Am Assoc Cancer Res (AACR) 2007,48: Abst 2188.
28. Mullender, M.G., Everts, V., Green, T.P., Klein-Nulend, J. Inhibition of osteoclastic bone resorption by the novel, potent, and selective c-Src/Abl kinase inhibitor, AZD0S3O. Proc Am Assoc Cancer Res (AACR) 2005,46: Abst 2923.
29. Helfrich, B., Frederick, B., Raben, D., Bunn, P.A. The dual specific Src/Abl kinase inhibitor AZD0530 inhibits in vitro growth and induces apoptosis in non-small cell lung cancer lines. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 585.
30. Mambou, P., Romanski, A., Bug, G. et al. The SRC-kinase inhibitor AZD0530 efficiently counteracts the transformation potential of BCR/ABL by targeting its kinase activity. Eur J Cancer Suppl [16th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Sept 28-Oct 1, Geneva) 2004] 2004, 2(8): Abst 364.
31. Logie, A., Jacobs, V., Fennell, M. et at. In vivo evaluation of efficacy and pharmacodynamic biomarkers of AZD0530, a dual-specific Src/Abl kinase inhibitor, in preclinical, subcutaneous xenograft models. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 617.
32. Green, T.P., Jacobs, V., Morgan, S.R., Fennell, M., Hannon, R.A., Clack, G. Investigating the activity of the dual-specific Src/Abl kinase inhibitor AZD0530 on potential markers of tumour invasion and bone resorption. 5th Int Symp Target Anticancer Ther (March 8-10, Amsterdam) 2007, Abst P201.
33. Logie, A., Martin, P.D., Partridge, E.A., Byatt, S.L., Whittaker, R.D., Green, T.P. Pharmacokinetics, tissue distribution and anti-tumor activity of the Src/Abl kinase inhibitor AZD0530 in a rat xenograft model. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5989.
34. Serrels, B., Green, T., Frame, M.C., Brunton, V.G. Suppression of tumour formation and malignant conversion in a mouse model of skin carcinogenesis by the dual Src/Bcr-Abl tyrosine kinase inhibitor AZD0530. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 3774.
35. Williams, E.D., Thompson, E.W., Sreedharan, D., Green, T.P. Inhibition of Src kinase with the dual Src/Abl kinase inhibitor AZD0530 reduces bladder tumour growth and the development of mixed osteolytic/osteosclerotic lesions in bone. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 50.
36. Boyer, B., Green, T. In vivo inhibition of NBT-II bladder cell metastasis by the Src kinase inhibitor AZD0530. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst A239.
37. Lockton, J.A., Smethurst, D., Macpherson, M., Tootell, R., Marshall, A.L., Clack, G., Gallagher, N.J. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 3125.
38. Trarbach, T., Drevs, J., Strumberg, D. et al. A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 3592.
39. Tabernero, J., Cervantes, A., Hoekman, K. et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. J Clin Oncol [43rd Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2007] 2007, 25(18, Suppl.): Abst 3520.
40. Eng, C., Kopetz, S., Morris, J. et al. Phase II study of the novel oral Srckinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst LB-76.
41. Eastell, R., Hannon, R.A., Gallagher, N., Glack, G., Macpherson, M., Marshall, A. The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(15, Suppl.): Abst 3041.
42. Hannon, R.A., Finkelman, R.D., Clack, G. et al. Effects on bone turnover of the potent, once-daily, oral Src inhibitor AZD0530 in patients with advanced solid malignancies. J Bone Miner Res [29th Annu Meet Am Soc Bone Miner Res (ASBMR) (Sept 16-19, Honolulu) 2007] 2007, 22(Suppl. 1): AbstW192.
43. Relative bioavailability of phase II and phase III formulations of AZD0530 (NCT00771979). ClinicalTrials.gov Web site, February 6, 2009.
44. AZD0530 phase II study in patients with advanced ovarian cancer (OVERT-1) (NCT00610714). ClinicalTrials.gov Web site, February 6, 2009.
45. Study to evaluate the safety and effects AZD0530 on prostate and breast cancer subjects with metastatic bone disease (NCT00558272). ClinicalTrials.gov Web site, February 6, 2009.
46. A placebo-controlled study of AZD0530 in patients with recurrent osteosarcoma localized to the lung (NCT00752206). ClinicalTrials.gov Web site, February 6, 2009.
47. AZD0530 in treating patients with metastatic or locally advanced breast cancer that cannot be removed by surgery (NCT00559507). ClinicalTrials.gov Web site, February 6, 2009.
48. AZD0530 in treating patients with previously treated metastatic pancreatic cancer (NCT00735917). ClinicalTrials.gov Web site, February 6, 2009.
49. AZD0530 in treating patients with recurrent locally advanced or metastatic soft tissue sarcoma (NCT00659360). ClinicalTrials.gov Web site, February 6, 2009.
50. AZD0530 in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (NCT00669019). ClinicalTrials.gov Web site, February 6, 2009.
51. AZD0530 in treating patients with relapsed or refractory thymoma or thymic cancer (NCT00718809). ClinicalTrials.gov Web site, February 6, 2009.
52. AZD0530 as first-line therapy in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer (NCT00607594). ClinicalTrials.gov Web site, February 6, 2009.
53. AZD0530 in treating patients with recurrent or metastatic head and neck cancer (NCT00513435). ClinicalTrials.gov Web site, February 6, 2009.
54. AZD0530 in treating patients with recurrent, stage IIIB or stage IV nonsmall cell lung cancer previously treated with combination chemotherapy that included cisplatin or carboplotin (NCT00638937). ClinicalTrials.gov Web site, February 6, 2009.
55. AZD0530 in treating patients with extensive stage small cell lung cancer (NCT00528645). ClinicalTrials.gov Web site, February 6, 2009.
56. AZD0S30 in treating patients with previously treated metastatic colon cancer or rectal cancer (NCT00397878). ClinicalTrials.gov Web site, February 6, 2009.
57. AZD0530 study 21 - Phase I study in patients with solid tumours (NCT00704366). ClinicalTrials.gov Web site, February 6, 2009.
58. Phase I study in patients with solid tumours (NCT00496028). ClinicalTrials.gov Web site, February 6, 2009.
59. Safety and tolerability study of AZD2171 in combination with AZD0530 in patients with advanced solid tumours (NCT00475956). ClinicalTrials.gov Web site, February 6, 2009.
60. Phase I study to assess absorption, metabolism & excretion of a single oral dose of [14C] AZD0S30 in healthy male volunteers (NCT008S3983). ClinicalTrials.gov Web site, February 6, 2009.
61. Hannon, R.A., Clack, G., Gallagher, N., Macpherson, M., Marshall, A., Eastell, R. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. Annu Meet Bone Tooth Soc (Juty 4-5, Birmingham) 2005, Abst OCI.
62. Rothschild, B.L., Frederick, B., Helfrich, B., Weed, S.A., Shim, A.H., Song, J., Raben, D. Combining the Src inhibitor, AZD0530, with ionizing radiation yields additive effects without modulation of phospho-sites on Src, EGFR or MAPK. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst A173.
63. Hannon, R.A., Clack, G., Swaisland, A., Churchman, C., Finkelman, R.D., Eastell, R. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. 27th Annu Meet Am Soc Bone Miner Res (ASBMR) (Sept 23-27, Nashville) 2005, Abst M251.
64. Green, T.P., Fennell, M., Whittaker, R. et al. Preclinical activity of AZD0530, a novel, oral, potent and selective inhibitor of the Src family kinases. Eur J Cancer Suppl [16th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Sept 28-Oct 1, Geneva) 2004] 2004, 2(8): Abst 361.
65. Hiscox, S., Morgan, L., Green, T., Nicholson, R. Reduction of in vitro metastatic potential of tamoxifen-resistant breast cancer cells following inhibition of Src kinase activity by AZD0530. Eur J Cancer Suppl [16th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Sept 28-Oct 1, Geneva) 2004] 2004, 2(8): Abst 406.
66. Hannon, R.A., Clack, G., Gallagher, N., Macpherson, M., Marshall, A., Eastell, R. The effect of AZD0530, a highly selective Src inhibitor, on bone turnover in healthy males. Bone [2nd Joint Meet Eur Calcified Tissue Soc Int Bone Miner Soc (June 25-29, Geneva) 2005] 2005, 36(Suppl. 2): Abst OC042.
67. Hiscox, S., Green, T.P., Nicholson, R.I. Combination therapy using AZD0530 and tamoxifen prevents antihormone resistance in breast cancer cells. 29th Annu San Antonio Breast Cancer Symp (Dec 14-17, San Antonio) 2006, Abst 5099.
68. Irby, R., Kline, C. Molecular pathways regulating AZD0530 reduction of human colon tumor metastasis. Eur J Cancer Suppl [18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther (Nov 7-10, Prague) 2006] 2006, 4(12): Abst 575.
69. Van Schaeyroeck, S., Kyula, J., Longley, D., Johnston, P. The interaction between the dual Src/Abl inhibitor AZD-0530 and chemotherapy in colorectal cancer cell lines. NCRI Cancer Conf (Sept 39-Oct 3, Birmingham) 2007, Abst B172.
70. Morgan, S.R., Green, T.P., Jacobs, V., Fennell, M., Hannon, R.A., Clack, G. Investigating the activity of the dual-specific Src/Abl kinase inhibitor AZD0530 on potential markers of tumour invasion and bone resorption. Ann Oncol 2007, 18(Suppl. 4): Abst P.201.
71. Jacobs, V., Green, T., Womack, C. et al. Establishing proof of mechanism for AZD0530, a Src inhibitor, by immunohistochemistry in a phase I clinical trial -Practical considerations for scoring and pathology panel review. NCRI Cancer Conf (Sept 30-Oct 3, Birmingham) 207, Abst A179.
72. Finkelman, R.D., Torti, F.M., Lipton, A. et al. A phase II pilot study of safety and effects on bone resorption of AZD0530 in prostate or breast cancer patients with bone metastases. J Bone Miner Res [29th Annu Meet Am Soc Bone Miner Res (Sept 15-19, Honolulu) 2007] 2007, 22(Suppt. 1): Abst W189.
73. Green, T., Hennequin, L.F., Ple, P.A., Jones, R.J., Clack, G., Gallagher, N. Preclinical and early clinical activity of the highly selective, orally available, dual Src/Abl kinase inhibitor AZD0530. Proc Am Assoc Cancer Res (AACR) 2006, 46: Abst SY13-3.
74. Gallagher, N.J., Lockton, A.J., Macpherson, M., Marshall, A., Clack, G. A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual-specific Src-Abl kinase inhibitor. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 3972.
75. Hiscox, S., Barrow, D., Green, T., Nicholson, R.I. Adhesion- independent focal adhesion kinase activation involves Src and promotes cell adhesion and motility in tamoxifen-resistant MCF-7 cells and is inhibited by the Src/Abl kinase inhibitor AZD0530. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 266.
76. Villingshoj, M., Andersen, P., Stockhausen, M., Ottesen, L., Poulsen, H. Improved response by co-targeting EGFR/EGFRvIII and c-Src. Proc Am Assoc Cancer Res (AACR) 2007,48: Abst 4016.
77. Brookes, A., Moiseeva, E., Berry, D.P., Manson, M. Diiindolylmethane demonstrates activity in preclinical models of colorectal carcinoma both as monotherapy and in combination with AZD0530, a Src inhibitor. NCRI Cancer Conf (Oct 5-8, Birmingham) 2008, Abst B120.